Neurocrine Biosciences, maker of experimental drugs for treating neurological and endocrine disorders, said May 6 it would cut its 120-person staff in half to conserve cash as it focuses on moving its midstage clinical programs into final Phase 3 trials...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • NEW: San Diego 500 — influential business leaders you need to know
Yours for only $129